January 11, 2023 04:45 PM ESTUpdated January 15, 11:12 PM
R&D
Pharma

Ex­perts talk IRA im­pacts as CMS an­nounces it will pub­lish first 10 drugs up for ne­go­ti­a­tion in Sep­tem­ber

Lei Lei Wu

News Reporter

Ex­perts went back and forth on the im­pacts of the In­fla­tion Re­duc­tion Act, or IRA, on the bio­phar­ma in­dus­try in a vir­tu­al pan­el host­ed by …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Trump names Johns Hop­kins re­searcher Mar­ty Makary to lead the FDA; al­so names CDC, Sur­geon Gen­er­al picks

FDA ap­proves Bridge­Bio's heart dis­ease drug, set­ting up com­pe­ti­tion with Pfiz­er, Al­ny­lam

Drug or bi­o­log­ic? An Eli Lil­ly law­suit could im­pact weight loss drug com­pounders

Sur­round­ed by AI bio gi­ants, tiny start­up Nabla Bio makes de no­vo an­ti­bod­ies look more like drugs 

RFK Jr. and Elon Musk want to ban phar­ma ads. They would­n't be the first to try

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times